Mission Therapeutics has begun a 36-patient Phase 1b study of MTX325, a drug aimed at clearing out damaged mitochondria in ...

The Boston company says the deal more than doubles its patient reach and opens a path to brain-based sleep testing in primary care from 2027.

After 12 weeks, members of Omada’s GLP-1 Care Track had lost more weight and shifted their body makeup more than people on ...

Organoids are full of cells that shouldn’t be there, and sorting them out wrecks the vasculature. SynBITE prunes in place instead.

Swiss fertility heavyweight bets on stem-cell-derived egg maturation – and on ovarian biology as a market worth owning.

XellSmart’s off-the-shelf XS411 lifted motor scores in nine patients, and its 30-person Phase II trial has finished enrolling ...

Rapalogix reports firmer, more elastic skin in a double-blind study of its longevity serum, and the details are worth a close ...

Cognito Therapeutics and the state’s Life Science Hub are building a statewide platform around its Alzheimer’s therapy, ...

Sironax is about halfway to its enrollment target in a Phase 2 trial of an oral NAMPT activator for adults with obesity.

GlobalData says more adults with type 2 diabetes in England hit blood sugar and weight targets on tirzepatide than on ...

Arrowhead says its RNAi drug crossed the blood-brain barrier in healthy volunteers and sharply lowered tau, a protein tied to Alzheimer’s.

Indianapolis-based Carnyx says its oral drug boosted NREM sleep in aged animals, and it has hired Chris Brearley as chief ...